Philip L De Jager

Columbia University, New York, USA.

Professor of Neurology in the Taub Institute for Research on Alzheimer’s disease and the Aging Brain and the Columbia Precision Medicine Initiative, Columbia University, New York, USA.

Dr. Philip De Jager is the Weil-Granat Professor of Neurology at Columbia University Medical Center, where he is the Chief of the Division of Neuroimmunology. The division consists of the Multiple Sclerosis Center, the Neuroinflammation Clinical Service, and the Center for Translational & Computational Neuroimmunology. The focus of the division is to characterize and target the role of the immune system in inflammatory diseases, neurologic complications of immunotherapy, and neurodegenerative diseases such as Alzheimer’s disease (AD), Amyotrophic Lateral Sclerosis, Multiple Sclerosis (MS), and Parkinson’s disease (PD).

After completing Yale University with a degree in Molecular Biophysics & Biochemistry as well as Medieval French literature, Dr. De Jager received a Ph.D. in Neurogenetics from Rockefeller University and an M.D. from Cornell University Medical College. He then completed his M.M.Sc. in Clinical Investigation at Harvard Medical School (HMS) and MIT. Dr. De Jager served as a neurology resident in the Partners Neurology program at Massachusetts General Hospital and Brigham and Women’s Hospital. He then joined the faculty at HMS, rising to the rank of Associate Professor before joining Columbia University Medical Center. He has been recognized for his leadership in the field of multiple sclerosis research with both the Harry Weaver Neuroscience Scholar Award (2008) and the Barancik Award for Innovation in MS Research (2014) by the National MS Society.

The goal of Dr. De Jager’s work as a clinician-scientist is to apply modern methods of human immunology, genomics, and computational biology to the understanding of common neurodegenerative diseases such as AD, PD, and MS. He has applied his discoveries from basic research to identify novel targets for drug development and to create novel tools to enhance clinical decision-making and prevent the onset of these neurodegenerative diseases.